STOCK TITAN

bluebird bio to Present at Jefferies Cell Therapy Virtual Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

bluebird bio (NASDAQ: BLUE) announced that its management team will participate in the Jefferies Cell Therapy Virtual Summit on October 6 at 2:00 p.m. ET. Investors can access the live webcast on the bluebird bio website under the Investors & Media section. The presentation will also be available for replay for 90 days after the event. Known for pioneering gene therapy, bluebird bio focuses on severe genetic diseases and cancer, aiming to improve healthcare access and education.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass.--()--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6, at 2:00 p.m. ET.

To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. Replays of the webcast will be available on the bluebird bio website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders, including cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using three gene therapy technologies: gene addition; cell therapy and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash., Durham, N.C., and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.

Contacts

Investors & Media

Investors:
Ingrid Goldberg, 857-217-0490
igoldberg@bluebirdbio.com
OR
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com

Media:
Jenn Snyder, 617-448-0281
jsnyder@bluebirdbio.com

FAQ

When is bluebird bio's presentation at the Jefferies Cell Therapy Virtual Summit?

bluebird bio will present at the Jefferies Cell Therapy Virtual Summit on October 6 at 2:00 p.m. ET.

How can I access the bluebird bio presentation?

You can access the live webcast of bluebird bio’s presentation on their website under the Investors & Media section.

Is the bluebird bio presentation available for replay?

Yes, the presentation will be available for replay for 90 days following the event.

What is the focus of bluebird bio's gene therapy?

bluebird bio focuses on developing gene therapies for severe genetic diseases and cancer.

What technologies does bluebird bio use in gene therapy?

bluebird bio utilizes gene addition, cell therapy, and megaTAL-enabled gene editing in its gene therapy approaches.

bluebird bio, Inc.

NASDAQ:BLUE

BLUE Rankings

BLUE Latest News

BLUE Stock Data

80.75M
193.91M
0.63%
43.76%
25.48%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOMERVILLE